Transferrin receptor is a marker of malignant phenotype in human pancreatic cancer and in neuroendocrine carcinoma of the pancreas

Ryschich, Eduard; Huszty, Gergely; Knaebel, H. P.; Hartel, Mark; Büchler, Markus W.; Schmidt, Jan

doi:10.1016/j.ejca.2004.01.036

Cited by 171 publications

(130 citation statements)

References 12 publications

Supporting

Mentioning

124

Contrasting

Order By: Relevance

“…Upregulation of CD71 in cancer cells is associated with malignant transformation. CD71 expression is particularly increased in metastatic and drug resistant tumors [33][34][35][36][37][38]. This makes CD71 both a tumor marker and a possible system for the delivery of small-molecule drugs to these cells by CD71-mediated endocytosis [39][40][41][42][43][44].…”

Section: Discussionmentioning

confidence: 99%

Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents

et al. 2017

View full text Add to dashboard Cite

Abstract:The ability of ferritin to bind and deliver metals and metal-based drugs to human neuroblastoma SH-SY5Y cells was studied. We used heavy chain (H) ferritin-based metal-containing nanocarriers to test whether these constructs, which are able to cross the blood-brain barrier, may be used for the delivery of toxic molecules to brain cells, and to study their effect on the viability and cellular redox homeostasis of human neuroblastoma cells. We show that metal-containing nanocarriers are efficiently captured by SH-SY5Y cells. Iron-containing nanocarriers have a proliferative effect, while silver and cisplatin-encapsulated nanocarriers determine concentration-dependent neuroblastoma cell death. This work is a proof of concept for the use of ferritins for the delivery of toxic molecules to brain tumors.

show abstract

Section: Discussionmentioning

confidence: 99%

Use of Ferritin-Based Metal-Encapsulated Nanocarriers as Anticancer Agents

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Over-expression of endogenous TfR has also been described for various cancers including those of lung [5,6], lymph nodes [7], colon [8], and pancreas [9], reflecting increased cell proliferation. This observation can in part be attributed to the increased need for iron as a cofactor for the ribonucleotide reductase enzyme involved in DNA synthesis of rapidly dividing cells [3].…”

Section: Introductionmentioning

confidence: 99%

Transferrin receptor (CD71) is a marker of poor prognosis in breast cancer and can predict response to tamoxifen

Habashy

Powe

Staka

et al. 2009

Breast Cancer Res Treat

200

138

View full text Add to dashboard Cite

International audienceTransferrin receptor (CD71) is involved in the cellular uptake of iron and is expressed on cells with high proliferation. It may be implicated in promoting the growth of endocrine resistant phenotypes within ER+/luminal-like breast cancer. We used a panel of in vitro cell models of acquired resistance to tamoxifen (TAMR), Faslodex (FASR) or severe oestrogen deprivation (MCF-7X) and the ER+ luminal MCF-7 parental line to determine CD71 mRNA expression and to study transferrin (Tf) effects on in vitro tumour growth and its inhibition. Furthermore, CD71 protein expression was assessed in a well-characterized series of patients with invasive breast carcinoma using tissue microarrays. Our results demonstrated a striking elevation of CD71 in all cell models of acquired resistance. Exogenous Tf significantly promoted growth in MCF-7-X and MCF-7 cells but more so in MCF-7-X; this growth was significantly reduced by Faslodex (FAS) or a phosphoinositide-3 kinase inhibitor (LY294002). Increased CD71 expression was associated with poor NPI score, tumour proliferation, basal CKs, p53, EGFR, HER2, steroid receptor negativity and shortened breast cancer specific survival ( < 0.001). On multivariate analysis, CD71 was found to be an independent prognostic factor in the ER+ cohort of patients. In conclusion, therapies of current interest in breast cancer (e.g. FAS, PI3K-inhibitors) appear able to partially impact on transferrin/CD71-promoted growth, but further investigation of this important mitogenic mechanism may assist in designing new therapeutic strategies to target highly proliferative, endocrine resistant breast cancers. CD71 appears to be a candidate marker of a subgroup of ER+/luminal-like breast cancer characterised by poor outcome and resistance to tamoxifen

show abstract

“…Binding assays showed that there is a good correlation between the affinity of gambogic acid derivatives to TfR and their ability to induce apoptosis. The binding site for (13) was found to be different from that of transferrin, suggesting a unique binding site and mechanism of action of these compounds [79]. Moreover, TfR was reported to be over-expressed in certain tumour types [79], suggestive that inhibitors of TfR could have useful anti-cancer activity.…”

Section: Gambogic Acid Derivativesmentioning

confidence: 99%